Reduced IkBα promotes hepatocellular carcinoma cell proliferation and migration via regulation of NF-κB/Erbin axis

YE TAN1, XIAO-TONG LIN1, YUAN-DENG LUO1, JIE ZHANG1, LEI FANG1, YAN-YIN ZHU1, HONG-QIANG YU1, LING SHUAI1, YAN JIANG1, LEI-DA ZHANG1, PING BIE1,2 and CHUAN-MING XIE1

1Key Laboratory of Hepatobiliary and Pancreatic Surgery, Institute of Hepatobiliary Surgery, Southwest Hospital, Army Medical University, Chongqing 400038; 2Department of Hepatobiliary and Pancreatic Surgery, The Third Affiliated Hospital of Chongqing Medical University, Chongqing 401120, P.R. China

Received March 23, 2020; Accepted June 19, 2020

DOI: 10.3892/ol.2020.12079

Abstract. Aberrantly low expression of NF-κB inhibitor α (IκBα) is observed in hepatocellular carcinoma (HCC), yet the underlying mechanism via which IκBα regulates HCC remains largely unknown. Therefore, to determine the potential function of IκBα in hepatocarcinogenesis, the present study used immunohistochemistry (IHC) staining to analyze the associations between IκBα protein expression and clinicopathologic characteristics of 107 patients with HCC. It was found that expression of IκBα was significantly associated with tumor recurrence. Moreover, IκBα protein expression was decreased in 107 HCC tissue samples and was positively associated with overall survival. Mechanistically, it was demonstrated that silencing of IκBα activated NF-κB in both Huh7 and HCCLM3 cells, followed by upregulation of Erbb2 interacting protein (Erbin) at both the mRNA and protein levels, confirmed by reverse transcription-quantitative PCR and western blotting, to promote cell proliferation and migration. Furthermore, knockdown of Erbin significantly attenuated NF-κB-mediated cell proliferation and migration. It was also identified that overexpression of Erbin in HCC tissues promoted both cell proliferation and migration, and was negatively associated with IκBα expression in 107 HCC tissue samples. Thus, these results indicated that downregulation of IκBα promoted HCC tumorigenesis via upregulation of NF-κB-mediated Erbin expression.

Introduction

Hepatocellular carcinoma (HCC) is one of the most malignant cancer types worldwide, especially in east Asia (1). Although significant improvements in diagnosis and treatment have been accomplished, the mortality rate for patients with HCC remains high, with ~782,000 deaths worldwide annually (1-3). The rapid and unnoticeable development and metastases of HCC are crucial to its progression, resulting in unresectable vascular thrombi, intrahepatic satellite nodules or cancer recurrence (4,5). Hence, it is important to discover effective diagnostic biomarkers to identify HCC in the early stage to improve the prognosis of patients with HCC.

NF-κB inhibitor α (IκBα) is an isoform in the IκB family, members of which have multiple ankyrin repeat domains at the C-terminus (6). IκBα combines with the NF-κB dimer to retain its existence in the cytoplasm and prevent its translocation into the nucleus (6). The IκB kinase (IKK) complex is induced by diverse extracellular signals, such as lipopolysaccharide, tumor necrosis factor (TNF) and growth factors, and the activated IKK complex phosphorylates IκBα. Then, phosphorylated IκBα is specifically recognized by an E3 ubiquitin ligase, leading to its ubiquitination and degradation (7). While previous studies have reported its inhibition of NF-κB, the remaining functions of IκBα in HCC are yet to be fully elucidated.

p65 is a well-known member of the NF-κB family of transcriptional factors participating in numerous pathways in biological responses, such as inflammation, adaptive immunity and stress reactions (8). Previous studies have revealed that NF-κB is involved in cancer oncogenesis and that it specifically promotes proliferation, metastasis and cell survival, particularly in inflammation-related cancer types (9,10). In healthy cells, activation of NF-κB after interaction with cellular stimuli occurs for a short duration and then returns to the inactive form. However, NF-κB is activated aberrantly in cancer cells, and thus continues to upregulate the transcription of its target gene (11). To achieve its transcriptional function, NF-κB/Rel proto-oncogene, NF-κB subunit (Rel) complex should shuttle to nucleus; but, IκBα combines with the dimer to anchor it in cytoplasm and thus inhibit its activity (8). After its phosphorylation is initiated by proinflammation
signals or immune stimulation, IkBα is degraded by the ubiquitin-proteasome system, which enables the NF-κB/Rel dimer to transllocate in nucleus (12). Therefore, reduced expression of IkBα is an important cause of the abnormal elevated expression of NF-κB in cancer cells.

Erbb2 interacting protein (Erbin) is a target gene of NF-κB, encoding Erbin. Containing 16 leucine-rich repeats and one PSD-95/Dlg/ZO-1 (PDZ) domain, Erbin is a member of the leucine-rich repeat and PDZ domain family (13). Furthermore, Erbin is an adaptor of the Erb-b2 receptor tyrosine kinase 2 (ERBB2) protein and, by binding with ERBB2, regulates its function and localization (13). Erbin has also been reported to be involved in several pathways (14). For instance, Erbin suppresses tumorigenesis via inhibiting Akt activity or Ras/Raf signaling (15,16). In addition, Erbin exerts an oncogetic function by activating estrogen receptor (ER) α or inhibiting STAT3 signaling (17,18). Thus, there is conflicting data regarding the role of Erbin in cancer. A previous study showed that Erbin is upregulated following exposure of macrophages to muramyl dipeptide, TNF α and lipopolysaccharide (19). Although it has been observed that Erbin is upregulated in HCC tissues, the underlying mechanism via which Erbin becomes dysregulated remains unknown.

The present study investigated the clinical importance of IkBα, Erbin and their molecular interactions, which suggested that reduced IkBα expression promoted HCC cell proliferation and migration via the NF-κB/Erbin pathway. Mechanistically, IkBα was downregulated in HCC tissues compared with healthy liver tissues, and decreased expression of IkBα weakened the inhibition of NF-κB. Abnormally activated NF-κB promoted Erbin expression at both the mRNA and protein levels, which served an oncogenic function in HCC. Moreover, IkBα was negatively associated with Erbin, and decreased IkBα and increased Erbin expression levels were associated with poor outcomes in patients with HCC. Therefore, the present results may facilitate the development of a potential strategy to target Erbin for HCC treatment.

**Materials and methods**

Patients with HCC and sample collection. In all, 107 human HCC tissue specimens were acquired from patients (aged between 19 and 73 years old, and 93 male, 14 female) between January 2011 and December 2013 at the Department of Hepatobiliary Surgery of Southwest Hospital, Army Medical University (Chongqing, China). All patients provided written informed consent and this study obtained approval from the Ethics Committee of Southwest Hospital. All patients used informed consent and this study obtained approval from the University (Chongqing, China). All patients provided written informed consent and this study obtained approval from the University (Chongqing, China).

To compare the difference of cell migration after different transfection, 5x104 cells were harvested for successive experiments.

Transwell migration assay. To compare the difference of cell migration after different transfection, 5x10^4-1.5x10^5 transfected

Cell culture and transfection. Huh7 and HCCLM3 cells were purchased from Fudan Cell Bank (Shanghai, China). Cells were maintained in DMEM (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin-streptomycin solution (Gibco; Thermo Fisher Scientific, Inc.), and cultured at 37˚C with 5% CO₂.

Cell transfection with plasmids (HA-tagged IkBα, Flag-tagged NF-κB p65 and corresponding empty vector as control; all Shanghai GeneChem Co., Ltd.) or small interfering RNAs (siRNAs; Shanghai GenePharma Co., Ltd.) was performed using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's instructions. In total, 400,000 cells/well were seeded into 6-well plates 1 day before transfection. Plasmids or siRNAs were diluted in Opti-MEM (Gibco; Thermo Fisher Scientific, Inc.) before mixing with Lipofectamine® 2000. Overexpression vector plasmids were pcDNA3.1 (Shanghai GeneChem Co., Ltd.). Each well of the 6-well plate was added with 2 μg plasmid for transfection. The sequences of siRNA oligos were: siIκBα, 5'-CUC CGAGACUUUUCCGAGGATT-3'; siNF-κB p65, 5'-GAUUUGGAGGAAACGUAAdTdT-3'; and siErbin, 5'-CACACUGUUGUAUGUACCCAU-3'. Each well of a 6-well plate was added with 8 μl siRNA (20 μmol/l) for transfection. After 48 h, cells were harvested for successive experiments.

**Immunohistochemistry (IHC) staining.** To perform IHC staining, sections were first deparaffinized, rehydrated and then boiled for 2.5 min in 100˚C 0.01 mol/l sodium citrate solution for antigen retrieval. Then the IHC detection kit (SP-9001; ZSGB-Bio, Beijing, China) was employed from blockage of peroxidase to incubation of secondary antibodies according to the manufacturer's instructions. Briefly, 3% H₂O₂ was used to block the endogenous peroxidase at room temperature for 15 min. After blocking with 5% goat serum at room temperature for 30 min, tissues were incubated with specific antibodies: Anti-IκBα (sc-945; 1:50 dilution; Santa Cruz Biotechnology, Inc.) and anti-Erbin (22438‑1‑AP; 1:50 dilution; ProteinTech Group, Inc.) overnight at 4˚C. The following day the sections were incubated with horseradish peroxidase-conjugated secondary antibody, before positive signals were detected using 3,3'-diaminobenzidine and nuclei were stained with hematoxylin at room temperature for 20 sec. After dehyadration, representative images were captured with an Olympus BX41 microscope under bright field (magnification, x100). Histological grading was referred to clinical standards (20).
cells were plated into an 8 µm-pore Transwell chamber, fit for a 24-well plate, with serum free-DMEM. The lower section of the chamber, a 24-well plate, contained normal medium with 10% FBS. FBS acted as attractant to stimulate cell migrate through the membrane of chambers. After incubating for 24 h, cells were fixed by 4% paraformaldehyde for 15 min at room temperature and stained with 0.1% crystal violet staining solution (Beijing Solarbio Science & Technology Co., Ltd.) at room temperature for 30 min. Three different fields were captured under bright field and cells were counted manually (magnification, x40).

RNA extraction and reverse transcription-quantitative (RT-q) PCR. RNA extraction, reverse transcription (RT) and real-time PCR were performed using RNAiso Plus, PrimeScript™ RT reagent kit with gDNA Eraser (Perfect Real Time) and TB
Green Premix Ex Taq (Tli RNaseH Plus) (all Takara Bio, Inc.), following the manufacturer's instructions. Temperature and duration for reverse transcription were 37°C for 15 min and 85°C for 5 min. The thermocycling conditions were as follows: Activation of enzyme at 95°C for 30 sec; 30 cycles of denaturation and annealing at 95°C for 5 sec and 60°C for 30 sec. GAPDH was used as the reference gene. The quantitative method to analyze relative gene expression was $2^{-\Delta\Delta Cq}$ (21). The 5'-3'sequences of primers used in RT-qPCR were as follows: GAPDH forward, TGGCACCCTGCAAGGGCCTGAA and reverse, TGGTGAACAGCAGCATTGGACTC; NF-κB p65 forward, CGCCTGCATCCACAGTCTTCCA and reverse, AGG GTGTTGTTGGTGTCTGG; Erbin forward, TGGTGGTGT GAAGACCTCAG and reverse, GTCCGATCTCCGCCCA TTTTC; c-Rel forward GGTGGTGGTCCTGCTCTTAC, and reverse, GCTGGAGTCCCAATGACGAA; and enhancer of zeste 2 polycomb repressive complex 2 subunit (Ezh2) forward, GGACCAAGTGTTACCAGCAT and reverse, GTG GGCTTTATCCGCTAG.

Western blot analysis. Proteins were extracted using RIPA lysis buffer (Beyotime Institute of Biotechnology) with complete protease inhibitor cocktail tablet (Bimake). Protein concentration was calculated by a BCA protein concentration kit (Beyotime Institute of Biotechnology) and 5X SDS loading buffer (Shanghai Shenggong Biology Engineering Technology Service, Ltd.) was added for extraction. The samples were gently vortexed and boiled at 100°C for 10 min before 30 µg was loaded onto 10% polyacrylamide gel (EpiZyme, Inc.). Following electrophoresis, proteins were transferred to nitrocellulose membranes. The membranes were blocked in 5% non-fat milk solution at room temperature for at least 1 h, incubated with primary antibodies at 4°C overnight and then HRP-conjunct secondary antibodies at room temperature for 1 h. Protein blots were detected using the super ECL kit (Nanjing KeyGen Biotech Co., Ltd.). Antibodies used in this study were: Anti-IκBα (sc-945, 1:600 dilution, Santa Cruz Biotechnology, Inc.); anti-NF-κB p65 (#8242, 1:10000 dilution, Cell Signaling Technology, Inc.); anti-GAPDH (10494-1-AP, 1:5000 dilution, Proteintech group, Inc.) and anti-Erbin (22438-1-AP, 1:500 dilution, ProteinTech group, Inc.).

Statistics analysis. Data are presented as the mean ± SEM, which represented ≥3 independent trials. Comparison between two different groups was performed using unpaired Student's t-test. Comparison among multiple groups was performed using one-way ANOVA and least significance difference was used as the post hoc test. $\chi^2$ test was used to detect associations between protein expression and clinical characteristics. Survival analysis was performed using Kaplan-Meier method and comparisons with the log-rank test. Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software, Inc.) and SPSS software (22.0 version; IBM Corp.). P<0.05 was considered to indicate a statistically significant difference.

Results

IκBα expression is downregulated in HCC and positively associated with poor prognosis of patients with HCC. The results indicated that IκBα protein expression was markedly decreased in HCC tissues compared with adjacent tissues (Fig. 1A). In total, 77.6% (83/107) of HCC cases exhibited low expression compared with the matched peri-tumor tissues. Knockdown of IκBα significantly promoted cell proliferation and migration, whereas overexpression of IκBα significantly inhibited cell proliferation and migration (Fig. 1B). These findings suggested that IκBα was downregulated in HCC tissues and that knockdown of IκBα was positively associated with poor prognosis of patients with HCC.

IκBα negatively regulates Erbin expression via NF-κB. Although it has been reported that elevated Erbin promotes HCC tumorigenesis (18), the underlying mechanism via which

- **Table I. Association between IκBα expression and clinicopathological variables of 107 patients with HCC.**

| Parameter (n=24) (n=83) | High (n=24) | Low (n=83) | $\chi^2$ | P-value |
|------------------------|------------|-----------|---------|---------|
| Sex                    |            |           |         |         |
| Male                   | 19         | 74        |         |         |
| Female                 | 5          | 9         |         |         |
| Age, years             |            |           |         |         |
| ≤50                    | 17         | 49        | 0.97    | 0.325   |
| >50                    | 7          | 33        |         |         |
| TNM stage              |            |           |         |         |
| I                      | 11         | 32        |         |         |
| II-IV                  | 13         | 51        |         |         |
| Tumor thrombi          |            |           |         |         |
| Yes                    | 4          | 25        | 1.706   | 0.192   |
| No                     | 20         | 58        |         |         |
| Histological grade     |            |           |         |         |
| I                      | 3          | 8         | 0.001   | 0.98    |
| II-III                 | 21         | 75        |         |         |
| Intrahepatic metastasis|            |           |         |         |
| Yes                    | 6          | 14        | 0.363   | 0.547   |
| No                     | 18         | 69        |         |         |
| Tumor recurrence       |            |           |         |         |
| Yes                    | 10         | 59        | 7.035   | 0.008*  |
| No                     | 14         | 24        |         |         |

Statistical analyses were performed using Pearson $\chi^2$ test. *P<0.05. IκBα, NF-κB inhibitor α.
Erbin is upregulated in HCC remains unknown. The results indicated that Erbin expression was upregulated in the HCC tissues from 107 patients in southwest of China (Fig. 2A). Kaplan-Meier survival analysis demonstrated that high expression of Erbin was positively associated with short survival time of patients with HCC (Fig. 2B). Moreover, expression of Erbin negatively regulates Erbin expression via NF-κB. (A) Representative images of HCC and adjacent liver tissues from 107 cases stained with anti-Erbin antibody. (B) Association between OS time of 107 patients with HCC and Erbin expression. Cells were transfected with (C) siIκBα or (D) HA-IκBα for 48 h and Erbin expression was determined using western blot analysis. Cells were transfected with (E) siIκBα or (F) HA-IκBα for 48 h and NF-κB p65 expression was determined using western blot analysis. (G) Cells were transfected with IκBα for 48 h and mRNA expression levels of c-Rel and Ezh2 were assessed using RT-qPCR. Cells were transfected with (H) Flag-NF-κB p65 or (I) siNF-κB p65 for 48 h and then the mRNA expression of Erbin was measured using RT-qPCR. Cells were transfected with (J) Flag-NF-κB p65 or (K) siNF-κB p65 for 48 h, then Erbin expression was determined using western blot analysis. Scale bar, 100 µm. The error bars represent SEM from three independent experiments. *P<0.05, **P<0.01 and ***P<0.001 vs. corresponding control group. siRNA, small interfering RNA; IκBα, NF-κB inhibitor α; Cont, control; HCC, hepatocellular carcinoma; OS, overall survival; Erbin, Erbb2 interacting protein; RT-qPCR, reverse transcription-quantitative PCR; Rel, Rel proto-oncogene, NF-kB subunit; Ezh2, enhancer of zeste 2 polycomb repressive complex 2 subunit.
was associated with malignant characteristics of HCC, such as TNM stage, existence of vascular tumor thrombi and cancer recurrence (Table II). As both IκBα and Erbin are associated with poor survival of patients with HCC, it was determined whether there was an association between IκBα and Erbin. It was found that knockdown of IκBα promoted Erbin protein expression, while overexpression of IκBα reduced this expression (Fig. 2C and D).

NF-κB/Rel transcription factors present in the cytosol in an inactive state form a complex with inhibitory IκB proteins (7). It has been suggested that NF-κB p65 is released from combination with IκBα and nuclear translocation occurs when IκBα is downregulated in HCC (6). The results indicated that knockdown of IκBα increased NF-κB p65 expression (Fig. 2E), while overexpression of IκBα inhibited NF-κB p65 expression (Fig. 2F). Subsequently, NF-κB activation upon IκBα knockdown was examined, as indicated by activation of canonical and non-canonical transcriptional targets of NF-κB, c-Rel and Ezh2 after transfection of silκBα (Fig. 2G).

To assess whether the transcription factor NF-κB regulates Erbin, the effect of knockdown or overexpression of NF-κB on Erbin at the mRNA and protein levels was measured. In contrast to IκBα, overexpression of NF-κB enhanced both mRNA and protein expression levels of Erbin, whereas knockdown of NF-κB inhibited these expression levels (Fig. 2H-K). Collectively, the results indicated that reduced IκBα promoted NF-κB-mediated Erbin expression at both mRNA and protein levels.

IκBα is negatively associated with Erbin in patients with HCC. To further evaluate the association between IκBα and Erbin, the expression levels of IκBα and Erbin were analyzed in 107 HCC tissues using IHC staining. It was determined that 77.6% of HCC samples were IκBα-negative or low expression, demonstrating active NF-κB signaling in the majority of cases (Fig. 3A and B). In line with this finding, Erbin protein expression in 58.9% (63/107) of cases was upregulated compared with the adjacent tissues. Thus, there was a negative association between IκBα and Erbin expression levels in HCC tissues (Fig. 3).

Erbin is responsible for NF-κB-mediated HCC cell proliferation and migration. Based on the oncogenic function of NF-κB (22) and its positive regulation over Erbin, it was evaluated whether Erbin was responsible for NF-κB-mediated cell proliferation and migration. Overexpression of NF-κB upregulated Erbin expression, and overexpression of Erbin exerted oncogenic effects on the proliferation and migration of HCC cells. However, knockdown of Erbin attenuated the aforementioned cellular abilities (Fig. 4A-F). In addition, increased proliferation and migration of HCC cells by NF-κB overexpression was reversed by Erbin knockdown (Fig. 4G-I), indicating that NF-κB promoted its activities via Erbin signaling. In healthy liver tissues, expression of IκBα limited the activity of NF-κB (6) and, in turn, its downstream target Erbin according to the present results. However, in HCC, NF-κB was abnormally activated due to the absence of IκBα, and transcriptionally upregulated expression of Erbin stimulated the proliferation and migration of HCC cells.

| Parameter      | (n=63) High | Low (n=44) | χ² | P-value |
|----------------|------------|------------|----|---------|
| Sex            | 0.195      | 0.659      |
| Male           | 54         | 39         |
| Female         | 9          | 5          |
| Age, years     | 0.009      | 0.926      |
| ≤50            | 39         | 27         |
| >50            | 24         | 16         |
| TNM stage      | 4.541      | 0.033*     |
| I              | 20         | 23         |
| II-IV          | 43         | 21         |
| Tumor thrombi  | 4.739      | 0.029*     |
| Yes            | 22         | 7          |
| No             | 41         | 37         |
| Histological grade | 0.000   | 0.988      |
| I              | 7          | 4          |
| II-III         | 56         | 40         |
| Intrahepatic metastasis | 2.640  | 0.014      |
| Yes            | 15         | 5          |
| No             | 48         | 39         |
| Tumor recurrence | 9.165   | 0.002*     |
| Yes            | 48         | 21         |
| No             | 15         | 23         |

Table II. Association between Erbin expression and clinicopathological variables of 107 patients with HCC.

Statistical analyses were performed using Pearson χ² test. *P<0.05.

Erbin, Erbb2 interacting protein.

Figure 3. IκBα is negatively associated with Erbin in patients with HCC. (A) Representative images of HCC and adjacent liver tissues from 107 cases stained with anti-IκBα and anti-Erbin antibodies. (B) There was a negative association between IκBα and Erbin expression levels. Scale bar, 100 µm. Erbin, Erbb2 interacting protein; IκBα, NF-κB inhibitor α; HCC, hepatocellular carcinoma.

Discussion

As HCC is a serious and lethal disease worldwide (1), and thus it is important to determine a novel therapeutic target. The present study identified that in HCC tissues, there was low expression of IκBα, the inhibitor of NF-κB, and decreased expression of IκBα promoted cancer cell proliferation and migration. Once IκBα undergoes proteasomal degradation, NF-κB activity is initiated (6), and positively affects cell proliferation and
Figure 4. Erbin is responsible for NF-xB-mediated HCC cell proliferation and migration. Cells were transfected with (A) HA-Erbin or (B) siErbin for 48 h and Erbin expression was determined by western blotting. Cells were transfected with (C) HA-Erbin or (D) siErbin and cell proliferation was assessed after 24 h of transfection using CCK-8 assay. After transfection with (E) HA-Erbin or (F) siErbin for 48 h, cells were seeded into Transwell plate for 24 h and stained with 0.1% crystal violet staining solution. Cells were transfected with Flag-NF-xB p65, with or without Erbin siRNA, and analyzed using (G) western blotting, (H) CCK-8 assay or (I) Transwell migration assay. Scale bar, 100 µm. The error bars represent SEM from three independent experiments. *P<0.05, **P<0.01 and ***P<0.001 vs. corresponding control group. siRNA, small interfering RNA; IκBα, NF-xB inhibitor α; Cont, control; Erbin, Erbb2 interacting protein; CCK-8, Cell Counting Kit-8.
migration by promoting the expression of Erbin. In the current study, consistent with previous reports of increased Erbin expression in HCC tissues obtained from Shanghai (18), the results indicated Erbin expression was upregulated in HCC tissues from 107 patients in southwest of China and exerted oncogenic functions. Moreover, downregulation of IkBα and upregulation of Erbin were closely associated with poor prognosis of patients with HCC. Therefore, the present results demonstrated the clinical importance of IkBα and Erbin, identified a novel association between IkBα/NF-κB and indicated the role of the downstream oncoprotein Erbin in the promotion of HCC tumorigenesis.

IkBα is considered to be a tumor-suppressing factor in different types of cancer, such as breast (23,24), ovarian (25), gastric (26) and colorectal (27), mainly due to its inhibition of NF-κB activity; however, the underlying mechanism is yet to be elucidated. Liver tumorigenesis is usually attributed to inflammation (28). Cell proliferation increases during inflammation, in which accelerated DNA replication results in the increased occurrence of oncogenic mutation (29). Moreover, NF-κB, as a hallmark of inflammation, not only participates in the initiation, but also maintains inflammation via blocking apoptosis, together with TNFα to activate anti-apoptosis genes (30). Thus, NF-κB serves a crucial role in promoting inflammation and contributing to malignancy (31).

Erbin has been reported to exert a range of diverse functions. For example, Erbin suppresses the activity of the Ras/Raf pathway to inhibit proliferation and stop epithelial-mesenchymal transition progress in colorectal cancer (32). Deficiency of Erbin significantly promotes ERK phosphorylation in ERBB2-overexpressed breast cancer (33). Furthermore, accumulation of Erbin attenuates Raf activation to halt autophagy and senescence in KRAS proto-oncogene, GTPase-induced skin tumorigenesis (34). Erbin also exerts a pro-tumorigenesis role by negatively regulating ERα (35). Therefore, these findings suggest that the function of Erbin depends closely on cell types or a certain cancer microenvironment. The current study demonstrated a novel signaling via which NF-κB promotes tumorigenesis. It was indicated that in HCC, Erbin is highly expressed and associated with poor prognosis of patients. In HCC cells, it was identified that NF-κB activated the expression of Erbin at both the mRNA and protein levels, and overexpression of Erbin enhanced cell proliferation and migration, while its knockdown reduced these abilities.

In conclusion, the present study identified that: i) IkBα was decreased in HCC and associated with poor survival of patients with HCC; ii) knockdown of IkBα upregulated NF-κB signaling to promote HCC cell proliferation and migration; and iii) NF-κB-mediated Erbin upregulation contributes to HCC cell proliferation and migration and a poor outcome of patients with HCC. Therefore, the present results indicated the important clinical implications of IkBα and Erbin, as well as the novel NF-κB/Erbin oncogenic pathway. Thus, disruption of this signaling pathway may be a novel strategy to slow the progression of HCC.

Acknowledgements

Not applicable.

Funding

This work was supported by the Introduction of Special Funds for Talents from Army Medical University (grant no. 4174C6), Natural Science Foundation of Chongqing (grant no. cstc2019jcyjmsxmX0519) and the Natural Science Foundation (grant no. 4241212162).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors’ contributions

CMX designed and supervised the study. YT, XTL, YDL, JZ, LF, YYZ, HQY and LDZ performed the experiments. YT, YYZ, HQY and CMX contributed to immunohistochemistry analysis and pathological analysis. YJ and LS contributed to the clinical sample collection, fixing and embedding, and pathological information processing. YT, PB and CMX analyzed and interpreted the data. YT and CMX drafted the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study was approved by the Ethics Committee of Southwest Hospital. The informed consent forms were obtained from the patients with HCC.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68: 394-424, 2018.
2. Negro F: Natural history of NASH and HCC. Liver Int 40 (Suppl 1): S72-S76, 2020.
3. Nahon P, Vibert E, Nault JC, Ganne-Carrie N, Ziol M and Seror O: Optimizing curative management of hepatocellular carcinoma. Liver Int 40 (Suppl 1): S109-S115, 2020.
4. Refolo MG, Messa C, Guerra V, Carr BI and D’Alessandro R: Inflammatory mechanisms of HCC development. Cancers (Basel) 12: 641, 2020.
5. Mohs A, Kuttkat N, Reissing J, Zimmermann HW, Sonntag R, Proudfoot A, Youssef SA, de Bruin A, Cubero FJ and Trautwein C: Functional role of CCL5/RANTES for HCC progression during chronic liver disease. J Hepatol 66: 743-753, 2017.
6. Hayden MS and Ghosh S: Shared principles in NF-kappaB signaling. Cell 132: 344-362, 2008.
7. Hoffmann A, Lechene A, Scott ML and Baltimore D: The IkappaB-NF-kappaB signaling module: Temporal control and selective gene activation. Science 298: 1241-1245, 2002.
8. Chen J and Chen ZJ: Regulation of NF-κB by ubiquitination. Curr Opin Immunol 25: 4-12, 2013.
9. Li Q and Verma IM: NF-kappaB regulation in the immune system. Nat Rev Immunol 2: 725-734, 2002.
10. Li Y, Lu L, Tu J, Zhang J, Xiong T, Fan W, Wang J, Li M, Chen Y, Steggerda J, et al: Reciprocal regulation between forkhead Box M1/NF-kB and methionine adenosyltransferase 1A drives liver cancer. Hepatology (Baltimore, Md.). Feb 21, 2020 doi: 10.1002/hep.31196. Online ahead of print.

11. Ghosh S and Karin M: Missing pieces in the NF-kappaB puzzle. Cell 109 (Suppl): S81-S96, 2002.

12. Gupta SC, Awasthee N, Rai V, Chava S, Gunda V and Challangundla KB: Long non-coding RNAs and nuclear factor-xB crosstalk in cancer and other human diseases. Biochim Biophys Acta Rev Cancer 1873: 188316, 2020.

13. Borg JP, Marchetto S, Le Bivic A, Ollendorff V, Jaulin-Bastard F, Saito H, Fournier E, Adelaide J, Margolis B and Birnbaum D: ERBIN: A basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor. Nut Cell Biol 2: 407-414, 2000.

14. Dan L, Shi M, Duan H, Han C and Guo N: Erbin, a negative regulator in diverse signal pathways. Curr Protein Pept Sci 11: 759-764, 2010.

15. Huang H, Song Y, Wu Y, Guo N, Ma Y and Qian L: Erbin loss promotes cancer cell proliferation through feedback activation of Akt-Skp2-p27 signaling. Biochem Biophys Res Commun 463: 370-376, 2015.

16. Huang YZ, Zang M, Xiong WC, Luo Z and Mei L: Erbin suppresses the MAP kinase pathway. J Biol Chem 278: 1108-1114, 2003.

17. Hu Y, Chen H, Duan C, Liu D, Qian L, Yang Z, Guo L, Song L, Yu M, Hu M, Shi M and Guo N: Deficiency of Erbin induces resistance of cervical cancer cells to anoikis in a STAT3-dependent manner. Oncogenesis 2: e52, 2013.

18. Wu H, Yao S, Zhang S, Wang JR, Guo PD, Li XM, Gan WJ, Mei L, Gao TM and Li JM: Elevated expression of Erbin destabilizes ERalpha protein and promotes tumorigenesis in hepatocellular carcinoma. J Hepatol 66: 1193-1204, 2017.

19. McDonald C, Chen FF, Ollendorff V, Ogura Y, Marchetto S, Lécine P, Borg JP and Nuñez G: A role for Erbin in the regulation of Nod2-dependent NF-kappaB signaling. J Biol Chem 280: 40301-40309, 2005.

20. Department of Medical Administration, National Health Commission of the People's Republic of China: Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition). Zhonghua Gan Zang Bing Za Zhi 28: 112-128, 2020 (In Chinese).

21. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.

22. Dolcet X, Llobet D, Pallares J and Matias-Guiu X: NF-xB in development and progression of human cancer. Virchows Arch 446: 475-482, 2005.

23. Liu B, Sun L, Liu Q, Gong C, Yao Y, Lv X, Lin L, Yao H, Su F, Li D, et al: A cytoplasmic NF-xB interacting long noncoding RNA blocks IxB phosphorylation and suppresses breast cancer metastasis. Cancer Cell 27: 370-381, 2015.

24. Ma C, Zuo W, Wang X, Wei L, Guo Q and Song X: Lapatinib inhibits the activation of NF-xB through reducing phosphorylation of IxB-a in breast cancer cells. Oncol Rep 29: 812-818, 2013.

25. Ataie-Kachoei P, Badar S, Morris DL and Pourgholami MH: Minocycline targets the NF-xB Nexus through suppression of TGF-beta-TAK1-IxB signaling in ovarian cancer. Mol Cancer Res 11: 1279-1291, 2013.

26. Rhoads MG, Kandarian SC, Pacelli F, Doglietto GB and Bossola M: Expression of NF-kappaB and IkappaB proteins in skeletal muscle of gastric cancer patients. Eur J Cancer 46: 191-197, 2010.

27. Lu YX, Ju HQ, Wang F, Chen LZ, Wu QN, Sheng H, Mo HY, Pan ZZ, Xie D, Kang TB, et al: Inhibition of the NF-xB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis. Cancer Lett 380: 87-97, 2016.

28. Feld JJ and Krassernburg LAP: What comes first: Treatment of viral hepatitis or liver cancer? Dig Dis Sci 64: 1041-1049, 2019.

29. Clevers H: At the crossroads of inflammation and cancer. Cell 118: 671-674, 2004.

30. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E and Ben-Neriah Y: NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431: 461-466, 2004.

31. Elsharkawy AM and Mann DA: Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 46: 590-597, 2007.

32. Stevens PD, Wen YA, Xiong X, Zaytseva YY, Li AT, Wang C, Stevens AT, Farmer TN, Gan T, Weiss HL, et al: Erbin suppresses KRAS1-mediated RAS/RAF signaling and tumorigenesis in colorectal cancer. Cancer Res 78: 4839-4852, 2018.

33. Liu D, Shi M, Duan C, Chen H, Hu Y, Yang Z, Duan H and Guo N: Downregulation of Erbin in Her2-overexpressing breast cancer cells promotes cell migration and induces trastuzumab resistance. Mol Immunol 56: 104-112, 2013.

34. Xie CM, Wei D, Zhao L, Marchetto S, Mei L, Borg JP and Sun Y: Erbin is a novel substrate of the Sag-TrCP E3 ligase that regulates KrasG12D-induced skin tumorigenesis. J Cell Biol 209: 721-737, 2015.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.